|
Adenocarcinoma of lung (disorder)
|
0.310 |
Biomarker
|
disease |
BEFREE |
Based on these findings, we infer that GOLM1 might serve as a valuable prognostic biomarker in LUAD, but not in LUSC.
|
29843532 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.310 |
Biomarker
|
disease |
CTD_human |
c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.
|
27602772 |
2016 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, in patients of autoimmune liver diseases, non-alcoholic fatty liver disease and viral hepatitis, serum GP73 also exhibited diagnostic value for advanced fibrosis as well as cirrhosis.
|
29256057 |
2018 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hepatocyte GP73 levels are upregulated in acute hepatitis and during the progression of liver disease to cirrhosis.
|
15180730 |
2004 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum GP73 is an important biomarker in evaluating and monitoring the disease progression including liver necroinflammation and fibrosis in patients with chronic HCV infection, but the value is limited for diagnosing advanced fibrosis and cirrhosis in comparison with APRI and FIB-4.
|
31636735 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Golgi protein 73 (GP73) is an independent diagnostic indicator of cirrhosis.
|
30486937 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicated that the background of cirrhosis was related to the elevation of serum GP73 in HCC patients.
|
28157705 |
2017 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated Golgi phosphoprotein 2 (GP73, also known as GOLPH2 or GOLM1) expression in serum and liver, which can be induced by viral infection and cytokine treatments, is intimately connected with liver disease, including acute hepatitis, cirrhosis and hepatocellular carcinoma (HCC).
|
29097707 |
2017 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
For patients with liver cirrhosis (n = 19), the AFP was 2.60 (1.70, 4.20) μg/l and GP73 was 136.10 (92.10, 261.70) μg/l, and for HCC patients (n = 36), the AFP was 13.65 (3.35, 158.88) μg/l and GP73 was 186.25 (96.73, 262.03) μg/l.
|
29630871 |
2018 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although there was an association between levels of GP73 and OSM in serum from people with liver cirrhosis, there was not a statistically significant correlation in HCC, suggesting that the role of the cytokines in determining circulating levels may be complex.
|
23144154 |
2012 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GP73 level in HCC group was significantly higher than LC group, chronic hepatitis B group, and healthy control group.
|
30488837 |
2019 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast to patients with cirrhosis and hepatitis, or healthy subjects, PHC patients had their serum GP73 and AFP significantly elevated (P < 0.05) while their PBMCs GP73 mRNA was not significantly different from those with cirrhosis and hepatitis, or healthy subjects (P > 0.05).
|
21517136 |
2011 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher alpha-fetoprotein (AFP), alpha-fetoprotein-L3 (AFP-L3), alanine aminotransferase (ALT), and AFP-L3/AFP ratio levels are potential risk factors for malignization in hepatic cirrhosis patients (RR = 2.99, 2.92, 2.72, and 2.34); serum Golgi protein 73 (GP73) level of hepatic cirrhosis patients decreased significantly after developing HCC (<i>t</i> = 2.212; <i>p</i> = 0.041).
|
28540298 |
2017 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the early warning biomarker, 3 or more anti-URGs were served as the threshold to separate the cirrhosis and HCC from others with a moderate sensitivity (58.3%) and specificity (80.0%), which was better than other biomarkers (AFP, AFP-L3, GPC3 and GP73) and would improve up to 70.3% when combined with another biomarker.
|
22820138 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Also GP73 mRNA expression level in peripheral blood mononuclear cells (PBMCs) and liver tissue between health controls and PHC patients was interrogated.
|
21517136 |
2011 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A multiplex assay for the simultaneous detection of GP73 and AFP with high sensitivity and accuracy was developed for the diagnosis of HCC.
|
31081083 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) and Golgi protein 73 (GP73) is a serum biomarker for liver diseases and HCC.
|
28394926 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, elevated GP73 mRNA expression levels in early HCC were significantly increased compared to those of TGF-β1 mRNA and to high serum AFP (92.3 vs. 53.8 and 23.1 %; P = 0.03 and 0.0004, respectively).
|
24186850 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we used MEIA based on magnetic nanoparticles to provide a screening method for fast analysis of serum Golgi protein 73 (GP73) in hepatocellular carcinoma (HCC) and healthy subjects and comparison was made with the enzyme-linked immunosorbent assay (ELISA) method.
|
29620331 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also evaluated the efficiency of serum GP73 measurement for the diagnosis of HCC using this assay.
|
25801213 |
2015 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, significant background of cirrhosis could have accounted for the elevation of serum GP73 in HCC.
|
29256057 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization.
|
28943903 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Golgi membrane protein GP73 modified-liposome mediates the antitumor effect of survivin promoter-driven HSVtk in hepatocellular carcinoma.
|
31306654 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Various studies have previously demonstrated that Golgi protein-73 (GOLPH2) is overexpressed in tumorigenesis, which has been observed in hepatocellular carcinoma and prostate cancer.
|
29344673 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results establish the linkage between GP73 and TGF-β signaling, indicating that GP73 may promote HCC tumorigenesis by selectively regulating TGF-β signaling through lipid raft modulation.
|
30615900 |
2019 |